An Open-label, Single-dose, Phase I Clinical Study to Assess the Pharmacokinetics and Safety of DBPR108 Tablets in Subjects With Varying Degrees of Renal Impairment Compared to the Control Subjects With Normal Renal Function
Latest Information Update: 19 May 2022
Price :
$35 *
At a glance
- Drugs Prusogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 06 May 2022 Status changed from recruiting to completed.
- 05 Aug 2021 Status changed from not yet recruiting to recruiting.
- 29 Apr 2021 New trial record